Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 68Inflammatory mediators and NSAID effectsAntiplatelet Therapy and Cardiovascular DiseasesEicosanoids and Hypertension Pharmacology

The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.

Cardiovascular Risk of Nonsteroidal Anti‐inflammatory Drugs and Classical and Selective Cyclooxygenase‐2 Inhibitors: A Meta‐analysis of Observational Studies

Open access
Martín Arias, Luis Hermenegildo, Martín González, Antonio, Sanz Fadrique, Rosario, Vazquez, Esther Salgueiro·2019·The Journal of Clinical Pharmacology
DOI 10.1002/jcph.1302
Open this paper in CoChat — free account

Abstract

The purpose of this study was to review the published evidence on the clinical use of nonsteroidal anti‐inflammatory drugs (NSAIDs) and to assess the cardiovascular risk (CVR) of cyclooxygenase‐2 inhibitors (coxibs), excluding aspirin, by means of a meta‐analytic procedure. A search was conducted on MEDLINE and EMBASE databases between October 1999 and June 2018. Cohort and case‐control studies showing CVR as relative risk (RR), odds ratio, hazard ratio, or incidence rate ratio associated with NSAIDs versus no treatment were selected. We estimated the pooled RR and the 95% confidence interval (CI) for all NSAIDs as a whole and individually. Eighty‐seven studies met the inclusion criteria. Overall, NSAIDs were found to be associated with a statistically significantly increased CVR (RR, 1.24 [95%CI, 1.19‐1.28]). The risk was slightly higher for coxibs (RR, 1.22 [95%CI, 1.17‐1.28]) as compared with nonselective NSAIDs (RR, 1.18 [95%CI, 1.12‐1.24]). Data analysis by drug disclosed that rofecoxib (RR, 1.39 [95%CI, 1.31‐1.47]), followed by diclofenac (RR, 1.34 [95%CI, 1.26‐1.42]) and etoricoxib (RR, 1.27 [95%CI, 1.12‐1.43]) were the NSAIDs associated with the highest CVR. Analysis by type of event showed that the highest risk corresponded to vascular events for both coxibs (RR, 2.18 [95%CI, 1.72‐2.78]) and nonselective NSAIDs (RR, 2.46 [95%CI, 2.00‐3.02]). The meta‐analysis results suggest that the use of the marketed coxibs celecoxib and etoricoxib would be related to a statistically significant CVR increase. Etoricoxib CVR could be higher than that for celecoxib. This increment would be similar to classical NSAID CVR.

Overview

Integrity signals

Registry

Crossref · 10.1002/jcph.1302

Cites

107 of 107 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 107 references

Research works printed but not linked: 3

  1. Higgins JPT, 2011, Manual Cochrane de revisionessistemáticas de intervenciones, Cochrane, 1
  2. Sanchez Serrano JL, 2015, Cardiovascular risk associated with the use of nonsteroidal anti‐inflammatory drugs, Rev Esp Salud Publica, 89, 607
  3. Gutiérrez Dávila JM, 2007, Texto de Cardiología [Cardiology Text], 1145

Cited by

See all 68

Related

See all

Metadata

Authors
Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S.
Affiliations
  • Centre for Drug Surveillance (CESME) School of Medicine, Valladolid University Valladolid Spain
  • Department of Pharmacy Sagrado Corazón Hospital Valladolid Spain
  • Centre for Drug Surveillance (CESME) School of Medicine, Valladolid University Valladolid Spain
  • Pharmacology, School of Medicine, Oviedo University Oviedo Spain
ORCID
Martín González, Antonio
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2018-09-11
Volume
59
Issue
1
Pages
55-73
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
DOI
10.1002/jcph.1302
OpenAlex
W2891937954
Cited by
68
References
107
Citations by year
2026: 6 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 1
FWCI
0.76
Type
journal article
Language
en
Open access
Licence
Locations
  • The Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Consultation of the Doctoral Thesis Database (TESEO) (Ministerio de Educación, Cultura y Deporte) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
cardiovascular risk, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, rofecoxib, diclofenac, etoricoxib, celecoxib, cardiovascular adverse events, vascular events, drug safety, relative risk, observational studies, non-selective NSAIDs
MeSH terms
Celecoxib, Etoricoxib, Anti-Inflammatory Agents, Non-Steroidal, Cardiovascular Diseases, Humans, Risk Factors, Cohort Studies, Case-Control Studies, Observational Studies as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular Risk of Nonsteroidal Anti‐inflammatory Drugs and Classical and Selective Cyclooxygenase‐2 Inhibitors: A Meta‐analysis of Observational Studies. https://app.cochat.ai/papers/10.1002/jcph.1302
The paper
Martín Arias, L. H., Martín González, A., Sanz Fadrique, R., & Vazquez, E. S. (2019). Cardiovascular Risk of Nonsteroidal Anti‐inflammatory Drugs and Classical and Selective Cyclooxygenase‐2 Inhibitors: A Meta‐analysis of Observational Studies. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.1302

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.